Publications by authors named "Rita C F Tavares"
Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus.
Infect Drug Resist
October 2018
Background: Direct-acting antiviral agents (DAAs) permit the use of interferon (IFN)-free regimens to treat hepatitis C (HCV) in patients with chronic kidney disease (CKD) on hemo-dialysis (HD) or renal transplant (RTx) recipients, with excellent response rates and safety. However, the occurrence of basal or therapy-induced resistance-associated substitutions (RASs) to DAAs can result in treatment failure. The aim of this study was to estimate the prevalence of RASs to NS3A, NS5A and NS5B inhibitors, and particularly the Q80K polymorphism, in CKD patients on HD and RTx recipients infected with HCV.
View Article and Find Full Text PDFArticle Synopsis
- NS3 protease inhibitors (PIs) are key antiviral treatments for hepatitis C, particularly beneficial for patients with chronic kidney issues who cannot use interferon.
- A study assessed the prevalence of resistance-associated variants (RAVs) in 67 patients undergoing dialysis or renal transplants, finding that 18% had mutations affecting PIs, mostly in those with GT1a infection.
- Despite the presence of these low-resistance variants, the Q80K polymorphism was rare, suggesting that PIs can still be effectively used in this patient population.
Background And Objectives: Prognosis of patients in the intensive care unit (ICU) has a relation with their severity just before admission. The Modified Early Warning Score (MEWS) was used to evaluate the severe condition of patients 12, 24 and 72 hours before admission in the ICU, assess the most prevalent parameters and correlate the MEWS before ICU with the outcome (survival versus death).
Methods: Retrospective analyses of 65 patients consecutively admitted to the ICU from July to October, 2006 evaluating the physiological parameters 72 hours prior to admission.